Rob Dillard

DocwireNews

<p>The findings of a <a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2736353">new study</a> published in <em>JAMA Internal Medicine</em> suggest an association between exposure to several types of strong anticholinergic drugs and an augmented risk of <a href="https://www.docwirenews.com/abstracts/aging-lifestyle-and-dementia/">dementia</a>.<p>Researchers of this nested case-control study recruited 284,343 patients (58,769 dementia patients and 225,574 matched controls, 63% women) 55 years and older (mean age, 82). They used prescription information on a total of 56 drugs with significant anticholinergic properties to calculate drug exposure. The primary exposure of this study was the total standardized daily doses (TSDDs) of any anticholinergics prescribed within the 10-year period prior to date of dementia diagnosis or the equivalent date with respect to the matched control group. Odds ratios (ORs) were used as the study measures, and data were analyzed from May 2016 to June 2018.</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Commonly prescribed drugs could increase the risk of <a href="https://twitter.com/hashtag/dementia?src=hash&amp;ref_src=twsrc%5Etfw">#dementia</a>, says a new study <a href="https://twitter.com/UniofNottingham?ref_src=twsrc%5Etfw">@UniofNottingham</a> <a href="https://twitter.com/JAMAInternalMed?ref_src=twsrc%5Etfw">@JAMAInternalMed</a> <a href="https://t.co/N2ZJpJuoSO">https://t.co/N2ZJpJuoSO</a></p>
<p>&mdash; Medical Xpress (@medical_xpress) <a href="https://twitter.com/medical_xpress/status/1143171934831677441?ref_src=twsrc%5Etfw">June 24, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><h2><strong>A Troubling Correlation</strong></h2><p>According to the results of the study, the adjusted OR for dementia climbed from 1.06 (95% CI, 1.03 to1.09) in the lowest overall anticholinergic exposure category to 1.49 (95% CI, 1.44 to 1.54) in the highest category, juxtaposed to no anticholinergic drug prescriptions in the 1 to 11 years before the index date. Moreover, the results suggest a significant increase in dementia risk for the anticholinergic antidepressants (adjusted OR [AOR], 1.29; 95% CI, 1.24-1.34), anti-parkinson drugs (AOR, 1.52; 95% CI, 1.16 to 2.00), antipsychotics (AOR, 1.70; 95% CI, 1.53 to 1.90), bladder antimuscarinic drugs (AOR, 1.65; 95% CI, 1.56 to 1.75), and antiepileptic drugs (AOR, 1.39; 95% CI, 1.22-1.57) all for more than 1095 TSDDs. According to the study authors, &ldquo;these results were similar when exposures were restricted to exposure windows of 3 to 13 years (AOR, 1.46; 95% CI, 1.41to 1.52) and 5 to 20 years (AOR, 1.44; 95% CI, 1.32 to 1.57) before the index date for more than 1095 TSDDs.&rdquo;</p><p>&ldquo;This study provides further evidence that doctors should be careful when prescribing certain drugs that have anticholinergic properties, said Tom Dening, Head of the Centre for Dementia at the University of Nottingham in a <a href="https://www.eurekalert.org/pub_releases/2019-06/uon-cdc062019.php">press release.</a> &ldquo;However, it&rsquo;s important that patients taking medications of this kind don&rsquo;t just stop them abruptly as this may be much more harmful. If patients have concerns, then they should discuss them with their doctor to consider the pros and cons of the treatment they are receiving.&rdquo;</p><p>&ldquo;Our study adds further evidence of the potential risks associated with strong anticholinergic drugs, particularly antidepressants, bladder antimuscarinic drugs, anti-Parkinson drugs and epilepsy drugs,&rdquo; stated lead researcher Professor Carol Coupland from the University&rsquo;s Division of Primary Care. &ldquo;The risks of this type of medication should be carefully considered by healthcare professionals alongside the benefits when the drugs are prescribed and alternative treatments should be considered where possible, such as other types of antidepressants or alternative types of treatment for bladder conditions. These findings also highlight the importance of carrying out regular medication reviews.&rdquo;</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Commonly prescribed drugs could increase the risk of dementia, says a new study <a href="https://t.co/KYzdscuMBG">https://t.co/KYzdscuMBG</a> via <a href="https://twitter.com/medical_xpress?ref_src=twsrc%5Etfw">@medical_xpress</a> <a href="https://twitter.com/hashtag/TuesdayThoughts?src=hash&amp;ref_src=twsrc%5Etfw">#TuesdayThoughts</a> <a href="https://twitter.com/hashtag/mentalhealth?src=hash&amp;ref_src=twsrc%5Etfw">#mentalhealth</a> <a href="https://twitter.com/hashtag/dementia?src=hash&amp;ref_src=twsrc%5Etfw">#dementia</a></p>
<p>&mdash; Harpreet Duggal, MD (@HDuggalMD) <a href="https://twitter.com/HDuggalMD/status/1143511420174102528?ref_src=twsrc%5Etfw">June 25, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><p>Source: <a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2736353">JAMA Internal Medicine</a>, <a href="https://www.eurekalert.org/pub_releases/2019-06/uon-cdc062019.php">EurekAlert</a></p></p>


Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Anticholinergic Drug Exposure Linked to an Increased Risk of Dementia

The findings of a new study published in JAMA Internal Medicine suggest an association between exposure to several types of strong anticholinergic drugs and an augmented risk ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe